Bristol-Myers Sues Synthon to Block Copies of Zeposia Drug

Bristol-Myers Squibb Co. sued Netherlands-based Synthon BV alleging its proposed copies of Zeposia infringe a patent for the drug, used to treat ulcerative colitis and relapsing forms of multiple sclerosis.

Synthon’s generic versions of Zeposia infringe US Patent No. 11,680,050, which covers specific crystalline forms of the drug’s active ingredient, ozanimod hydrochloride, and a method for preparing them, Bristol-Myers and its Receptos LLC unit said in a complaint filed Tuesday in the US District Court for the District of Delaware.

Synthon didn’t immediately respond to a request for comment.

• The patent expires in September 2038, according to the US ...